Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Kiora Pharmaceuticals (KPRX) Asset Writedowns and Impairment (2023 - 2024)

Kiora Pharmaceuticals' Asset Writedowns and Impairment history spans 3 years, with the latest figure at -$1.9 million for Q4 2024.

For Q4 2024, Asset Writedowns and Impairment fell 200.2% year-over-year to -$1.9 million; the TTM value through Dec 2025 reached $104167.0, down 97.33%, while the annual FY2024 figure was $104167.0, 94.52% down from the prior year.
Asset Writedowns and Impairment reached -$1.9 million in Q4 2024 per KPRX's latest filing, down from $2.0 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $2.0 million in Q3 2024 to a low of -$1.9 million in Q4 2024.